CENTER
VALLEY, Pa., May 15, 2024
/PRNewswire/ -- Olympus, a global medical technology company
committed to making people's lives healthier, safer and more
fulfilling, announced today that it will highlight its
algorithm-powered emphysema screening program along with two
exciting bronchoscopes compatible with the EVIS X1™ endoscopy
system as part of the Olympus Hybrid Bronchoscopy Solution during
the annual American Thoracic Society meeting May 17-22 in San
Diego.
SeleCT™ Screening, an algorithm-driven screening process,
reviews existing chest CT scans to help identify patients who would
benefit from bronchoscopic lung volume reduction (BLVR).
BLVR with endobronchial valves such as the Spiration™ Valve may
improve lung function by redirecting air away from hyperinflated
portions of the lung to healthier portions.1
Study results show that patients treated with the Spiration
Valve System experienced a significant improvement in lung
function, respiratory symptoms and quality-of-life scores at 24
months. Now with the addition of SeleCT Screening, an algorithm can
help healthcare providers find more appropriate patients,
potentially bringing BLVR with the Spiration Valve to even more
patients suffering with emphysema.
Chronic Obstructive Pulmonary Disease (COPD), which includes
emphysema, is a commonly undiagnosed lung disease with studies
showing that as many as 80% of adults with COPD worldwide are
undiagnosed. Early detection of COPD is important because properly
managing the disease has shown to reduce the risk of future
exacerbations and hospitalizations and to alleviate
symptoms.2
Potential adverse events which may be associated with the use of
the Spiration Valve System may include, but are not limited to,
pneumothorax, worsening of COPD symptoms, pneumonia, and dyspnea. A
full list of prescriptive information and additional information on
indications, contraindications, warnings, precautions and potential
complications is available here.
Compatible with the EVIS X1™ endoscopy system, the BF-H1100
diagnostic bronchoscope and the BF-1TH1100 therapeutic bronchoscope
each feature a compact outer diameter and large working channel, as
well as high-definition imaging.
Education will be a primary focus at this year's annual ATS
meeting with Olympus hosting a series of workshops and peer-to-peer
hands-on experiences on various topics, including:
- EVIS X1 endoscopy system with Prof. Felix Herth, MD – Dr. Herth discusses how
the imaging modalities available on the EVIS X1 endoscopy system
can assist physicians in detecting, characterizing and sampling
pulmonary disorders.
- The Role of Single-Use Bronchoscopes in the Bronch
Lab – Dr. Sonali Sethi will
discuss her perception of single-use bronchoscopes and their role
in the bronch lab in the future.3
- Postoperative Prolonged Air Leaks with
the Spiration™ Valve System – Dr.
Roy Cho reviews a unique
postoperative prolonged air leak case utilizing the Spiration Valve
System.3
Spiration Valve is authorized by federal law as a Humanitarian
Use Device for use in the control of prolonged air leaks of the
lung or significant air leaks that are likely to become prolonged
air leaks, following lobectomy, segmentectomy, or Lung Volume
Reduction Surgery (LVRS). The effectiveness of this device for this
use has not been demonstrated. Potential complications which may be
associated with bronchoscopy and/or the Spiration Valve System may
include, but are not limited to, pneumothorax, atelectasis,
pneumonia, shortness of breath, and in rare cases, death. A full
list of prescriptive information and additional information on
indications, contraindications, warnings, precautions and potential
complications is available here.
For more information about the pulmonology portfolio, visit the
Olympus booth, #2543, during ATS or visit the pulmonology product
page for more detail.
About Olympus
At Olympus, we are committed to our purpose of making people's
lives healthier, safer and more fulfilling. As a global medical
technology company, we partner with healthcare professionals to
provide solutions and services for early detection, diagnosis and
minimally invasive treatment, aiming to improve patient outcomes by
elevating the standard of care in targeted disease states.
For more than 100 years, Olympus has pursued a goal of
contributing to society by producing products designed with the
purpose of delivering optimal outcomes for its customers around the
world.
Olympus Corporation of the Americas, a wholly owned subsidiary
of Olympus Corporation, is headquartered in Center Valley, Pennsylvania, USA, and employs
more than 4,500 employees throughout locations in North and
South America. For more
information, visit olympusamerica.com.
1 Criner GJ, Delage A, Voelker K, et al.
Improving Lung Function in Severe Heterogenous Emphysema with the
Spiration Valve System (EMPROVE). A Multicenter, Open-Label
Randomized Controlled Clinical Trial. Am J Respir Crit Care Med.
2019;200(11):1354-1362. doi:10.1164/rccm.201902-0383OC
2 Lin CH, Cheng SL, Chen CZ, Chen CH, Lin SH, Wang
HC. Current Progress of COPD Early Detection: Key Points and Novel
Strategies. Int J Chron Obstruct Pulmon Dis.
2023;18:1511-1524. Published 2023 Jul 19.
doi:10.2147/COPD.S413969
3 Drs. Sethi and Cho are paid consultants for
Olympus Corp. of the Americas
View original content to download
multimedia:https://www.prnewswire.com/news-releases/olympus-highlighting-copd-treatment-ai-driven-screening-process-and-evis-x1-bronchoscopes-at-american-thoracic-society-annual-meeting-302146289.html
SOURCE Olympus Corporation of the Americas